A multicenter effort validated that aliquoting Locametz cold kits and coordinating generator elutions under strict volume limits can expand Ga-68 prostate cancer imaging capacity. The approach also aimed to cut diagnostic costs while maintaining safe radiopharmaceutical output. For centers running high-volume PSMA or prostate imaging workflows, this is a practical operational update: it focuses on kit handling logistics and production scaling rather than new clinical trial evidence. The immediate industry relevance is throughput and cost control in nuclear medicine supply chains, particularly where generator elution efficiency and kit storage/aliquoting constraints drive schedule bottlenecks.